Plainsboro, NJ, United States of America

Xiaoqing Xu



 

Average Co-Inventor Count = 4.8

ph-index = 4

Forward Citations = 41(Granted Patents)


Location History:

  • Spring House, PA (US) (2012 - 2014)
  • Plainsboro, NJ (US) (2007 - 2017)

Company Filing History:


Years Active: 2007-2017

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Xiaoqing Xu

Introduction

Xiaoqing Xu is a prominent inventor based in Plainsboro, NJ (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target pain management. With a total of 10 patents to her name, her work has the potential to impact various medical conditions.

Latest Patents

Among her latest patents are innovative compounds such as benzimidazole derivatives, which serve as modulators for the TRPM8 channel. These compounds are designed to treat a range of diseases, syndromes, conditions, and disorders, including pain. Another notable patent involves cold menthol receptor antagonists, which also aim to address similar medical challenges. Both patents showcase her commitment to advancing therapeutic options for patients.

Career Highlights

Xiaoqing Xu has worked with reputable organizations, including Janssen Pharmaceutica. Her experience in these companies has allowed her to collaborate on groundbreaking research and development projects that focus on improving patient outcomes.

Collaborations

Throughout her career, she has collaborated with esteemed colleagues such as Mingde Xia and Mark J Macielag. These partnerships have further enriched her research and contributed to her success as an inventor.

Conclusion

Xiaoqing Xu's innovative work in the pharmaceutical industry highlights her dedication to addressing critical health issues. Her patents and collaborations reflect her significant impact on pain management and therapeutic advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…